CCM
RNAM

CAAS Capital Management’s Avidity Biosciences RNAM Stock Holding History

CAAS Capital Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25,000
Closed -$555K – 878
2022
Q4 		$555K Buy
+25,000
New +$373K 0.03% 379
2021
Q4 		– Sell
-140,354
Closed -$3.46M – 1016
2021
Q3 		$3.46M Buy
+140,354
New +$3.05M 0.07% 264
2020
Q4 		– Sell
-15,000
Closed -$422K – 912
2020
Q3 		$422K Hold
15,000
– – 0.01% 402
2020
Q2 		$424K Buy
+15,000
New +$432K 0.01% 326

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

CAAS Capital Management's RNAM Position: Q1 2023 in Review

CAAS Capital Management sold out of Avidity Biosciences (RNAM) in Q1 2023, closing a stake of 25,000 shares — an estimated $555K sold.

CAAS Capital Management first reported a position in RNAM in Q2 2020 and held it in 4 quarters. The position peaked at $3.46M in Q3 2021. 139 funds tracked by Wall St. Rank hold RNAM as of Q1 2023.

  • CAAS Capital Management reported no remaining Avidity Biosciences position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 25,000 Avidity Biosciences shares in Q1 2023, an estimated $555K.
  • CAAS Capital Management first reported a position in Avidity Biosciences in Q2 2020 and held it in 4 quarters.
  • CAAS Capital Management's Avidity Biosciences position peaked at $3.46M in Q3 2021.
  • 139 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.